Video

Dr. Ross on Biomarker Research Development in Liver Metastasis

Author(s):

Merrick I. Ross, MD

Merrick I. Ross, MD, professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses biomarker research development for patients with liver metastasis.

Merrick I. Ross, MD, professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses biomarker research development for patients with liver metastases.

The most important unmet challenge need in the treatment of these patients is better biomarkers, states Ross. Having biomarkers would allow physicians to know which patients will benefit from immunotherapy regimens.

Additionally, biomarkers will help determine who will develop a resistance to immunotherapy so alternative therapies can be identified for the patient, explains Ross.

Related Videos
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.
Related Content
Revumenib in NPM1+ R/R AML | Image Credit: © LASZLO– stock.adobe.com
November 12th 2024

Revumenib Meets CR/CRh End Point in NPM1+ R/R AML

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
October 30th 2024

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

Vinayak Venkataraman, MD
November 11th 2024

Personalized Initiatives Empower Patients to Actively Participate in Cancer Research

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

DLL3-TOPAbody
November 8th 2024

Preclinical Activity Support DLL3-TOPAbody in DLL3-Expressing SCLC and Other Tumors

Lung Cancer - stock.adobe.com
November 8th 2024

FDA Approval Sought for Sunvozertinib in Pretreated EGFR Exon 20+ Advanced NSCLC